As the Head CMC & Industrialization, PS Biotech & CGT unit at Bayer Pharmaceuticals, Dirk Böhm leads and coaches a cross-functional team responsible for process development, quality, manufacturing, and regulatory aspects of cell and gene therapy products. He has over 20 years of experience in international biotech and pharma manufacturing settings, with a strong track record of delivering excellent results efficiently and reliably to high quality standards.

His mission is to bring innovative therapies to patients through collaboration and excellence in execution across the Bayer CGT companies and the units in the Bayer group. He is passionate about building efficient teams and organizations, developing talent, and creating a motivating environment. He is also focused on continuous improvement and a clear strategy and direction to bring the best performance year over year. He is an innovation ambassador of the organization, supporting and enabling scouting of external technology and business opportunities.

Timo Flessner, Senior Vice President, has broad operational and senior management experience in pharmaceutical R&D, manufacturing & Product Supply.

Since June 2024 he takes the role as the Manufacturing API & Medical Devices Lead at Bayer Pharma Product Supply. The portfolio in API and MD manufacturing, is rich in diversity and complexity, spans across 11 global sites. MD adds to his former responsibility and brings new challenges as change, fostering collaboration, and setting new benchmarks in the supply of active pharmaceutical ingredients and a diverse portfolio of medical devices.

Since October 2020 he took responsibility for the Global API (Active Pharmaceutical Ingredient) Product Supply organization. The main focus is on API supply for clinical studies as well as launch & the longer-term commercial life-cycle of a broad product portfolio.

In the previous role he was the Site Manager for the Pharma site in Wuppertal - which is the founding place of Bayer & includes Pharma R&D and API Product Supply operations. Before he was the Site Manager for the Bayer Supply Center Bergkamen as well as the Supply organization in Berlin-Charlottenburg. Before moving into the site manager responsibilities he was heading Global Chemical Development with a focus on the development of chemical & technological processes to ensure API supply concepts & security for preclinical, clinical studies, submission & launch.

From 2000-2011 he held various positions of increasing responsibility in Bayer´s / Bayer HealthCare’s Global Drug Discovery (Head of chemistry labs, Chief of staff for PH Research and PH R&D, Director & Head of a Medicinal Chemistry Department).

In addition to his responsibilities at Bayer he is a non-executive advisor for start-up companies and a lecturer at the University of Hannover since 2015 (Making Drugs: Research, Development & Industrialization of API). His strong ambition for sustainability drove him into a supporter role for the Circular Valley initiative. In an additional assignment he is a member of the board of the GDCh (2016-2024). Apart from the professional level he is active in voluntary work, e.g. in an initiative in Wuppertal that supports the city & people in need. He is married and a proud father of two sons.

He holds a PhD in Chemistry. He was educated at the Universities of Oldenburg, Hannover and Paris-Sud (Diploma in Chemistry). He received his PhD with Prof. E. Winterfeldt in 1999 from the University of Hannover. He worked as a Postdoc in the group of Prof. C.-H. Wong at the Scripps Research Institute in San Diego.

Bayer ist ein internationales Life-Science-Unternehmen mit einer über 160-jährigen Geschichte und Kernkompetenzen in den Gebieten Gesundheit und Agrarwirtschaft. Der Bayer-Konzern wird über die drei Divisionen Pharmaceuticals, Consumer Health und Crop Science geführt. Weltweit gliedert sich das Unternehmen in rund 354 Gesellschaften in 83 Ländern (2022) auf. Unser Unternehmenszweck „Science for a better life“ spiegelt sich in der Entwicklung bahnbrechender Innovationen in der medizinischen Versorgung und in der Landwirtschaft wider. Wir tragen dazu bei, Lösungen für das Wachstum und die Folgen des zunehmenden Alterns der Weltbevölkerung sowie für die steigende Belastung der natürlichen Ökosysteme zu finden. Kurz: Wir wollen unsere Vision „Health for all, hunger for none“ realisieren.

Bayer is a global enterprise with core competencies in the life science fields of healthcare and nutrition. We design our products and services to serve the most essential human needs of health and nutrition. At the same time, we strive to address some of the world’s biggest challenges presented by a growing and aging global population. At Bayer, we’re committed to driving sustainable development and generate a positive impact with our businesses. Through the power of science, we’re pioneering new possibilities that advance life for all of us. That means reimagining how we care for ourselves and one another by empowering everyday health, improving approaches to patient care, and finding better ways to nourish our communities around the world.